Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects

NCT04367441 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Plaque Psoriasis

Interventions

DRUG: 608
DRUG: Placebo

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.